Deutsche Bank analyst Neena Bitritto-Garg initiated coverage of Neurocrine Biosciences with a Buy rating and $136 price target. The analyst sees potential for share upside into 2024 on crinecerfont in congenital adrenal hyperplasia, which the firm says could be on market as soon as 2025 in the U.S., and from mid/late-stage clinical successes. It thinks the Street is currently underestimating peak sales potential for crinecerfont.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
- Neurocrine receives FDA Breakthrough Therapy designation for crinecerfont
- Neurocrine price target raised to $139 from $134 at JPMorgan
- Neurocrine announces settlement of INGREZZA ANDA litigation
- Neurocrine price target lowered to $121 from $128 at RBC Capital